Share

October 15, 2013; 81 (16) Article

Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis

Clemens Warnke, Anne K. Mausberg, Mark Stettner, Thomas Dehmel, Lina Nekrich, Gerd Meyer zu Horste, Hans-Peter Hartung, Anna Fogdell-Hahn, Ortwin Adams, Bernd C. Kieseier
First published September 18, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182a84101
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
328

Share

Article Information

vol. 81 no. 16 1400-1408
DOI: 
https://doi.org/10.1212/WNL.0b013e3182a84101
PubMed: 
24049136
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 1, 2013
  • Accepted in final form June 12, 2013
  • First Published September 18, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Clemens Warnke, MD*,
    2. Anne K. Mausberg, PhD*,
    3. Mark Stettner, MD,
    4. Thomas Dehmel, MSc,
    5. Lina Nekrich,
    6. Gerd Meyer zu Horste, MD,
    7. Hans-Peter Hartung, MD,
    8. Anna Fogdell-Hahn, PhD,
    9. Ortwin Adams, MD and
    10. Bernd C. Kieseier, MD
  1. Clemens Warnke, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. CW has received compensation for travel expenses from TEVA Pharma.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS)fellowship stipend to Dr. Warnke, 2011 and 2012

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anne K. Mausberg, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. travel expenses from Grifols

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mark Stettner, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Thomas Dehmel, MSc,
    5. Scientific Advisory Boards:

    1. (1) Novartis Pharma Scientific Advisory Board Meeting, San Francisco, March 2013

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis Pharma, financial support for travel and congress registration fee (2) Bayer HealthCare, financial support for travel and congress registration fee

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lina Nekrich,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Gerd Meyer zu Horste, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) biogen idec, travel funding (2) TEVA pharmaceuticals, travel funding

    Editorial Boards:

    1. (1) European Journal of Medical Research, associate editor, 2012

    Patents:

    1. (1) US registration 60/969,381 “9-amino-acridine derivates and method of treating autoimmune diseases using the same”; patent to treat autoimmune disorders with novel compound Quinpramin

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Grifols, project funding

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) German Research Association (DFG), project funding (2) Fritz-Thyssen foundation, project funding

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Hans-Peter Hartung, MD,
    8. Scientific Advisory Boards:

    1. Novartis; Merck Serono; Teva; Biogen Idec; Roche; Genzyme; BayerHealthcare; Sanofi

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker Honoraria from: Biogen Idec Teva Sanofi Aventis Merck Serono Novartis ; Bayer Schering

    Editorial Boards:

    1. board member: annals of neurology, journal of neuroimmunology, multiple sclerosis

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Anna Fogdell-Hahn, PhD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Informa March 2013 London, UK, invited speaker, travel and hotel paid.

    Editorial Boards:

    1. Associated editor from 2010 for: Drugs and Therapy Studies (http://www.pagepress.org/journals/index.php/dts)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) BiogenIdec unrestriced research grant (2) Merck Serono unrestricted research grant (3) Sanofi Aventis unrestricted research grant

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) IMI - Innovative Medicines Initiative,ABIRISK.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Ortwin Adams, MD and
    10. Scientific Advisory Boards:

    1. On April 11th 2013 I participated on a expert meeting of Biogen Idec in Munich about the topic “Risk stratification for developing PML of MS patients with Natalizumab. I was not involved in any strategic or other decisions of Biogen Idec. I got a honorarium for participating.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Bernd C. Kieseier, MD
    11. Scientific Advisory Boards:

    1. Commercial - Biogen Idec Commercial - Novartis Commercial - Sanofi Aventis Commercial - Roche Commercial - Merck Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Commercial - Biogen Idec Commercial - Novartis Commercial - Sanofi Aventis Commercial - Bayer Schering Commercial - Merck Serono Commercial - Teva

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (C.W., A.K.M., M.S., T.D., L.N., G.M.z.H., H.-P.H., B.C.K.) and Institute for Virology (O.A.), Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; and the Department of Clinical Neuroscience (C.W., A.F.-H.), Karolinska Institutet, Stockholm, Sweden.
  1. Correspondence to Dr. Warnke: clemenswarnke{at}googlemail.com
View Full Text

Article usage

Article usage: October 2013 to May 2023

AbstractFullPdfSource
Sep 2013353147Highwire
Oct 201314262580Highwire
Nov 20133001131Highwire
Dec 2013205413Highwire
Jan 2014971316Highwire
Feb 20148134Highwire
Mar 2014691414Highwire
Apr 20146831Highwire
May 20145254Highwire
Jun 20143962Highwire
Jul 201453126Highwire
Aug 20144145Highwire
Sep 20143757Highwire
Oct 20144912Highwire
Nov 20142136Highwire
Dec 20142563Highwire
Jan 20151600Highwire
Feb 20152333Highwire
Mar 20154876Highwire
Apr 20151811Highwire
May 20151900Highwire
Jun 20151410Highwire
Jul 20153431Highwire
Aug 20151643Highwire
Sep 20154576Highwire
Oct 20151145Highwire
Nov 20151901Highwire
Dec 20152422Highwire
Jan 2016810Highwire
Feb 20161910Highwire
Mar 2016721Highwire
Apr 20161831Highwire
May 20161721Highwire
Jun 20161400Highwire
Jul 20161122Highwire
Aug 20161310Highwire
Sep 20164210Highwire
Oct 20161100Highwire
Nov 20161411Highwire
Dec 20161700Highwire
Jan 20173422Highwire
Feb 2017331Highwire
Mar 20172844Highwire
Apr 2017711Highwire
May 20171700Highwire
Jun 2017600Highwire
Jul 2017500Highwire
Aug 2017200Highwire
Sep 2017344Highwire
Oct 20171132Highwire
Nov 2017341Highwire
Dec 2017600Highwire
Jan 20181221Highwire
Feb 2018713Highwire
Mar 20181800Highwire
Apr 20182721Highwire
May 20181811Highwire
Jun 20183911Highwire
Jul 20183022Highwire
Aug 20181400Highwire
Sep 20181201Highwire
Oct 2018910Highwire
Nov 20182420Highwire
Dec 20182010Highwire
Jan 20193110Highwire
Feb 20192142Highwire
Mar 2019600Highwire
Apr 20191410Highwire
May 20191723Highwire
Jun 2019900Highwire
Jul 20192420Highwire
Aug 20191430Highwire
Sep 2019800Highwire
Oct 20193522Highwire
Nov 20193133Highwire
Dec 2019711Highwire
Jan 20201600Highwire
Feb 20202100Highwire
Mar 20202300Highwire
Apr 20201401Highwire
May 20201600Highwire
Jun 2020712Highwire
Jul 20201700Highwire
Aug 20201500Highwire
Sep 20201421Highwire
Oct 2020200Highwire
Nov 20202410Highwire
Dec 20202110Highwire
Jan 20211110Highwire
Feb 20213502Highwire
Mar 20211530Highwire
Apr 20211521Highwire
May 20212540Highwire
Jun 2021900Highwire
Jul 20213010Highwire
Aug 20212110Highwire
Sep 20213034Highwire
Oct 20214022Highwire
Nov 20212500Highwire
Dec 20213010Highwire
Jan 20221931Highwire
Feb 20223300Highwire
Mar 20224610Highwire
Apr 20221150Highwire
May 20221711Highwire
Jun 20222100Highwire
Jul 2022801Highwire
Aug 2022900Highwire
Sep 20222600Highwire
Oct 20222400Highwire
Nov 20221100Highwire
Dec 2022900Highwire
Jan 20231900Highwire
Feb 20231700Highwire
Mar 20231910Highwire
Apr 20231821Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles